.jpg)
Next-generation diabetes management Glyntis™
An intelligent self-regulating drug delivery system.
Overview
Diabetes remains one of the most challenging chronic conditions globally, affecting millions of people and animals alike. Despite advances like insulin pumps and continuous glucose monitors, nearly 50% of patients do not achieve target glucose control, leading to complications and increased healthcare costs.
Our next-generation, self-regulating, glucose-responsive drug delivery platform offers a device-free, pain-free solution that closely mimics the body’s natural insulin regulation. Available in two formats — a microneedle patch and injectable glucose-sensitive nanoparticles — the platform automatically releases insulin when glucose levels rise and slows release as glucose normalises, reducing hypoglycaemia risk and treatment burden.
How It Works
Our platform integrates glucose sensing and therapeutic release in a single system.
It's available in two forms:
Microneedle Patch
Pain-free, dissolvable, and disposable. Designed for daily use, it provides seamless glucose-responsive insulin delivery.
Injectable Nanoparticles
Biodegradable drug storage depot that responds to glucose levels in real time, enabling targeted therapy without active patient intervention.
Key Benefits
Device-free and stress-free
Removes the need for pumps, reduces reliance on CGMs, manual dose adjustments and most importantly the needle pain.
Reduces hypoglycaemia risk
Insulin release automatically adjusts in response to glucose fluctuations.
Improves adherence and quality of life
Patients and animal owners no longer manage complex routines.
Cost-effective & scalable
Low production costs enable broad access, including low- and middle-income countries.
Translational potential
Applicable to both human and veterinary diabetes care, addressing global need.
Applications & Market Potential
Our technology is designed for diverse settings: hospitals, primary care, home-based care, and veterinary clinics. It also has potential for other anti-diabetics such as GLP-1 analogues etc, and other glucose-sensitive therapies, broadening the platform’s utility.
Globally, with over 81% of people with diabetes living in low- and middle-income countries, the platform’s scalable, affordable design can transform diabetes care worldwide. In veterinary markets, it addresses a growing need for stress-free, easy-to-administer glucose management in pets and the horse racing/breeding sector.
We are actively exploring potential applications and collaborations of this technology within wound care, fermentation and bioreactor industry and food packaging sectors.
Our Team
If you can spare 2 minutes, please complete the short survey below.
Website powered by
